How effective is platinib in treating lung cancer?

Lung cancer is a complex disease, and its cure rate is affected by many factors, such as the specific type and stage of lung cancer, the patient's overall health status, and the treatment plan chosen. Against this background, pralsetinib (Pralsetinib), as a targeted therapy, provides a new treatment option for patients with specific types of lung cancer. Platinib is mainly targeted at patients with RET gene fusion-positive non-small cell lung cancer. In some clinical studies, the drug has demonstrated significant anti-tumor activity, helping patients relieve symptoms and extend survival. However, it should be noted that platinib is not a panacea, and its therapeutic effect varies from person to person.

The U.S. Food and Drug Administration (FDA) approved platinib based on a multicenter, non-randomized, open-label Phase 1/2 clinical trial called ARROW. The study enrolled a diverse cohort of patients with metastatic RET fusion-positive NSCLC, some of whom had progressed on platinum-based chemotherapy and others who were treatment-naïve. Platinib demonstrated encouraging therapeutic effects in these patients, with both overall response rate and duration of response meeting expectations.

In theARROW trial, 87 patients with RET fusion-positive non-small cell lung cancer who had previously received platinum-based chemotherapy were treated with platinib. The results showed that the overall response rate (ORR) reached 57%, the complete response rate (CR) was 5.7%, and the median duration of response (DoR) has not yet been reached. Among 27 patients with newly treated non-small cell lung cancer, the ORR was as high as 70%, and the CR rate also reached 11%. These data undoubtedly provide strong support for the efficacy of platinib in the treatment of lung cancer.

However, we must also be aware that each patient's condition is unique and may respond differently to medications. Therefore, the cure rate of platinib cannot simply be attributed to "high" or "not high". In fact, the treatment of lung cancer is a highly individualized process, and multiple factors need to be considered to formulate the best treatment plan. In addition to drug treatment, surgery, radiotherapy, chemotherapy and other methods are also commonly used methods to treat lung cancer. Moreover, factors such as the patient's age, physical condition, tumor stage and characteristics will also have an important impact on the treatment effect.

When selecting a treatment plan, the doctor will conduct a comprehensive assessment based on the patient's specific situation and develop a treatment plan that is most suitable for the patient. No matter which treatment method you choose, it is crucial to maintain a positive attitude, cooperate with your doctor's treatment plan, and pay attention to a healthy lifestyle. Only through comprehensive treatment and care can the cure rate and quality of life of lung cancer patients be maximized.